Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Plus Therapeutics stock
Learn how to easily invest in Plus Therapeutics stock.
Plus Therapeutics Inc is a biotechnology business based in the US. Plus Therapeutics shares (PSTV) are listed on the NASDAQ and all prices are listed in US Dollars. Plus Therapeutics employs 14 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Plus Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PSTV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Plus Therapeutics stock price (NASDAQ: PSTV)Use our graph to track the performance of PSTV stocks over time.
Plus Therapeutics shares at a glance
|Latest market close||$0.54|
|52-week range||$0.41 - $2.80|
|50-day moving average||$0.62|
|200-day moving average||$1.15|
|Wall St. target price||$5.33|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.96|
Buy Plus Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Plus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Plus Therapeutics price performance over time
|1 week (2022-06-24)||8.00%|
|1 month (2022-05-31)||-3.50%|
|3 months (2022-03-31)||-46.00%|
|6 months (2021-12-31)||-48.57%|
|1 year (2021-07-02)||-77.59%|
|2 years (2020-07-02)||-74.53%|
|3 years (2019-07-02)||116.95%|
|5 years (2017-06-30)||1.1|
Plus Therapeutics financials
|Gross profit TTM||$-5,323,000|
|Return on assets TTM||-39.74%|
|Return on equity TTM||-122.5%|
|Market capitalisation||$11.1 million|
TTM: trailing 12 months
Plus Therapeutics share dividends
We're not expecting Plus Therapeutics to pay a dividend over the next 12 months.
Have Plus Therapeutics's shares ever split?
Plus Therapeutics's shares were split on a 1:50 basis on 5 August 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Plus Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Plus Therapeutics shares which in turn could have impacted Plus Therapeutics's share price.
Plus Therapeutics share price volatility
Over the last 12 months, Plus Therapeutics's shares have ranged in value from as little as $0.41 up to $2.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Plus Therapeutics's is 0.4152. This would suggest that Plus Therapeutics's shares are less volatile than average (for this exchange).
Plus Therapeutics overview
Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc.
Plus Therapeutics in the news
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Frequently asked questionsWhat percentage of Plus Therapeutics is owned by insiders or institutions?
Currently 1.654% of Plus Therapeutics shares are held by insiders and 14.704% by institutions. How many people work for Plus Therapeutics?
Latest data suggests 14 work at Plus Therapeutics. When does the fiscal year end for Plus Therapeutics?
Plus Therapeutics's fiscal year ends in December. Where is Plus Therapeutics based?
Plus Therapeutics's address is: 4200 Marathon Boulevard, Austin, TX, United States, 78756 What is Plus Therapeutics's ISIN number?
Plus Therapeutics's international securities identification number is: US72941H4002 What is Plus Therapeutics's CUSIP number?
Plus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23283K105
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert